Nat Commun. 2026 Feb 19. doi: 10.1038/s41467-026-69548-0. Online ahead of print.

ABSTRACT

Indirect hepatotoxicity remains a major challenge in drug development because of limited evaluation tools and mechanistic insight. Here, we construct three-dimensional multi-lineage hepatic organoids comprising five liver cell types derived from human embryonic stem cells, and in a screen of 58 hepatotoxic drugs, identify imipramine as an inducer of indirect hepatotoxicity. Imipramine specifically engages tyrosine kinase receptor B expressed by non-parenchymal hepatic stellate cells, activating the p53/hnRNPA2B1/DGCR8 pathway, which drives selective enrichment of microRNA-34a-3p in hepatic stellate cell-derived exosomes, thereby converting them into toxic exosomes. These toxic exosomes transfer microRNA-34a-3p to hepatocytes, where it disrupts cellular homeostasis by downregulating the anti-apoptotic protein XIAP, thereby activating caspase3 and inducing apoptosis. Consistently, imipramine long-term gavage in vivo triggers hepatic stellate cell apoptosis and toxic exosome-mediated hepatocyte injury without direct hepatocyte toxicity. Our findings establish a biomimetic organoid platform for precision drug testing and highlight the central role of intercellular communication in drug-induced liver injury.

PMID:41714631 | DOI:10.1038/s41467-026-69548-0